Recently，Johnson & Johnson's largest subsidiary Xi'an Yangsen Pharmaceutical Co., Ltd. (hereinafter referred to as Xi'an Yangsen) announced，The first new type of anti -wetting biological preparation of Windwither Wicker Biological Preparation of the first monthly injection of the undergrodia (Gorimu Mupage Anti -Anti -injection) was approved to be listed in China，This has become the only imported Gorimu monoclonist injection that has been approved to be listed so far。Xi'an Yangsen said，This drug is facing the drug market space of more than 10 million types of rheumatoid and ankylosing spondylitis in China。

From sales to solution

Xi'an Yangsen is the first multinational pharmaceutical company to enter the Chinese market，It is also the earliest pharmaceutical company that entered the Chinese market after reform and opening up。Xi'an Yangsen has survived in China for more than 30 years，Over the years, there have been heavy products in China。This time Xinpuni launched，Xi'an Yangsen is while further expanding the product line in the field of immunotherapy，It also announced the stake sports betting appopening Stake Sports Bettingof a new service era。Xi'an Yangsen Pharmaceutical Co., Ltd. Asgar Rangoonwala, President of Xi'an Yangsen Pharmaceutical Co., Ltd.，New product listing simultaneously launched the history of Yang Sen's fastest service patient，is a one -stop solution。

It is understood，At present, the drug market of patients with ankylosing spondylitis and rheumatoid arthritis has imported and national biopodium，For example, Ada Mutu monetab and injection of type II tumor necrosis factor receptor antibody fusion protein, etc.，But all are short -term medication，that is, twice a week or a month。Shipny is the first monthly injection of under -per month in China，better than the effectiveness of other drugs in the current drug market，Anti -ated biological preparations that can be injected by yourself。It is used to treat active adeptic spinalitis adult patients，and moderate to severe rheumatoid arthritis adult patients。The information hidden in this product characteristics is，Patients in this disease can be separated from the hospital for the first time、Clinic environmental medication，You can give it at home。The listing of Henpuni provides a brand new for doctors and patients in the family rheumatism、Efficient，Patient -centric treatment selection。

Chairman of the Rheumatology Branch of the Chinese Medical Association、Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology, Beijing Union Hospital, revealed，China has 10 million strong spinalitis and rheumatoid arthritis patients，Some patients even complete walking、jump、Simple movements such as bending fingers are extremely difficult。Zeng Xiaofeng said，The field of rheumatism and immunity has contained more than 200 million patients in China，Among them, rheumatoid arthritis、Two diseases of ankylosing spondylitis。From the perspective My stake betting appof age distribution，Patients stake online sports bettingare in the family、The age phase of the responsibility of society and the country，They are paying attention to cure，Also effectively relieve symptoms、Reducing the impact of disease on work and life has a strong demand。For convenience and long -term validity，Undoubtedly making Hampuni a pharmaceutical product in the field of disease in China。

For the field of ankylosing spondylitis disease，The entire set of treatment solutions provided by Xi'an Yangsen are divided into three parts，The first is a pharmacy navigation，Provide information at the level of Yang Sen，What pharmacies can patients understand、Which hospitals can provide products。The second is which pharmacies when the patient knows、After the hospital can provide products，You can submit the demand for purchasing drugs online，Direct medicine from the pharmacy to home，Convenient for patients for medication。The third is to provide patients with relevant remote health consulting information，Under professional medical persons help patients answer questions related to diseases。

Asgar called，Xi'an Yang Sen is not concerned about selling medicines，What is more concerned about what kind of treatment ending can the final patient。So Xi'an Yangsen not only considers research and development products、Transfer product，At the same time, it is necessary to consider what kind of support can the treatment enterprise around the patient with。Future，Xi'an Yangsen will continue to introduce more global innovative product portfolios and solutions。

Business layout

Xi'an Yangsen will continue to introduce innovative products like Henpuni to meet the treatment needs of Chinese patients。It is understood，Xi'an Yangsen will successively go public in China to treat patients with schizophrenia.、Treatment of Enlin and Persie in patients with stake online sports bettinghuman Stake Sports Bettingimmune defect virus infection，and the treatment of Yikean, who treats adult patients with type 2 diabetes。Xi'an Yangsen's heavy medicines in the Chinese market and earlier introduced the treatment of chronic lymphocyte leukemia and lymphoma、Zeke, who treats prostate cancer，and the treatment of multi -drug tuberculosis。

Asgar pointed out，Xi'an Yangsen's current overall business layout has a total of seven major business units: blood tumor、Immune and infectious diseases、physical tumor、Psychiatric Section、Neurology、Pharmaceutical (cough, cold, fever/digestion)、Pircea/Anti -Allergy。In the field of mental illness，Xi'an Yangsen's main research and development direction is schizophrenia、Diseases related to depression and children's polympidation。In the field of immune disease，Xi'an Yangsen will focus on rheumatoid arthritis、Drug development of inflammatory bowel disease and psoriasis。The field of Yangsen, Xi'an Yangsen，Contains blood tumors、Tumor、immune disease、Neuroscience、Infectious disease、pulmonary hypertension。In the field of infectious diseases，Xi'an Yangsen is concerned about AIDS and Multinational Tuberculosis。The field of blood disease is very large、A wide range of disease fields，Xi'an Yangsen Following B -cell lymphoma，Not long ago, a new drug "Yike"。

Demand for the Chinese market，Multiple MyEeloma Pharmaceutical R & D (MULTIPLE MyLOMA) drug research and development in the tumor field，Except Wanke, which has been listed,, Xi'an Yangsen is planning to be listed in China as soon as possible。Daramumab/Darzalex can target the cross -membrane extracellular enzyme CD38 molecule, which is highly expressed by the surface height of multiple osteoma cells.，Quick death of tumor cells through multiple mechanisms。In addition，Xi'an Yangsen also carries stake betting appout the cooperation project of stake online sports bettingthe chimeric antigen receptor T cell immunotherapy (CAR-T) that targeted B-cell mature antigen (BCMA) in the field of MM.。

In addition to the clear division of labor in the field of research and development，Xi'an Yang Sen in medical affairs、Business Affairs、Customer support management and other departments have made corresponding adjustments，Actively integrate into the "Internet +" and comprehensive services that provide the entire process of patient treatment。Xi'an Yangsen opened a patient support project- "Wen Xin Station" WeChat public platform。Patients after the prescription can directly obtain the drug sales information around WeChat account，You can buy or choose to send medicine for your own。Reporter found it when trial，"Wen Xin Station" cooperated with Dr. Chunyu，Provide guidance for patients and treatment。